Literature DB >> 14648318

[What do we know about the state of chronic pain?].

S C Azad1, W Zieglgänsberger.   

Abstract

Chronic pain syndromes are characterized by altered neuronal excitability in the pain matrix. The ability to rapidly acquire and store memory of aversive events is one of the basic principles of nervous systems throughout the animal kingdom. These neuroplastic changes take place e. g. in the spinal cord, in thalamic nuclei and cortical and subcortical (limbic) areas integrating pain threshold, intensity and affective components. Chronic inflammation or injury of peripheral nerves evokes the reorganisation of cortical sensory maps. Neurons conveying nociceptive information are controlled by various sets of inhibitory interneurons. The discharge activity of these interneurons counteracts long-term changes in the pain matrix following nociceptor activation, i. e. it prevents the transition of acute pain signaling to chronic pain states. Our most recent research suggests that pain states may be sensitive to novel families of agents and therapeutic measures not predicted by traditional preclinical pain models as well as human pain states. The endogenous cannabinoid system plays a central role in the extinction of aversive memories. We propose that endocannabinoids facilitate extinction of aversive memories via their selective inhibitory effects on GABAergic networks in the amygdala.

Entities:  

Mesh:

Year:  2003        PMID: 14648318     DOI: 10.1007/s00482-003-0257-3

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  16 in total

Review 1.  Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain.

Authors:  R R Ji; C J Woolf
Journal:  Neurobiol Dis       Date:  2001-02       Impact factor: 5.996

2.  [Deficits in the psychological care of low back pain patients--Comments on the expertise of the expert committee for the health care system regarding low back pain].

Authors:  H D Basler
Journal:  Schmerz       Date:  2002-06       Impact factor: 1.107

3.  Neural circuitry underlying pain modulation: expectation, hypnosis, placebo.

Authors:  Alexander Ploghaus; Lino Becerra; Cristina Borras; David Borsook
Journal:  Trends Cogn Sci       Date:  2003-05       Impact factor: 20.229

Review 4.  Phantom-limb pain: characteristics, causes, and treatment.

Authors:  Herta Flor
Journal:  Lancet Neurol       Date:  2002-07       Impact factor: 44.182

Review 5.  Action potential initiation and backpropagation in neurons of the mammalian CNS.

Authors:  G Stuart; N Spruston; B Sakmann; M Häusser
Journal:  Trends Neurosci       Date:  1997-03       Impact factor: 13.837

6.  Precisely localized LTD in the neocortex revealed by infrared-guided laser stimulation.

Authors:  H Dodt; M Eder; A Frick; W Zieglgänsberger
Journal:  Science       Date:  1999-10-01       Impact factor: 47.728

Review 7.  NMDA receptors as targets for drug action in neuropathic pain.

Authors:  C G Parsons
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

8.  Roles of capsaicin-insensitive nociceptors in cutaneous pain and secondary hyperalgesia.

Authors:  W Magerl; P N Fuchs; R A Meyer; R D Treede
Journal:  Brain       Date:  2001-09       Impact factor: 13.501

Review 9.  Endocannabinoid signaling in the brain.

Authors:  Rachel I Wilson; Roger A Nicoll
Journal:  Science       Date:  2002-04-26       Impact factor: 47.728

10.  The endogenous cannabinoid system controls extinction of aversive memories.

Authors:  Giovanni Marsicano; Carsten T Wotjak; Shahnaz C Azad; Tiziana Bisogno; Gerhard Rammes; Maria Grazia Cascio; Heike Hermann; Jianrong Tang; Clementine Hofmann; Walter Zieglgänsberger; Vincenzo Di Marzo; Beat Lutz
Journal:  Nature       Date:  2002-08-01       Impact factor: 49.962

View more
  11 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  [Psychoreactive disorders after motor vehicle accidents. Is it possible to predict the development of psychoreactive disorders after motor vehicle accidents?].

Authors:  C Meyer; U Dittrich; S Küster; E Markgraf; G O Hofmann; B Strauss
Journal:  Unfallchirurg       Date:  2005-12       Impact factor: 1.000

Review 3.  [Orthopedic aspects in interdisciplinary multimodal therapy of chronic back pain].

Authors:  L Weh; U Marnitz
Journal:  Schmerz       Date:  2011-06       Impact factor: 1.107

4.  [High-dose dronabinol treatment vs. medicinal cannabis flowers].

Authors:  Christoph Wendelmuth; Knud Gastmeier
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

Review 5.  [Dronabinol in geriatric pain and palliative care patients : A retrospective evaluation of statutory-health-insurance-covered outpatient medical treatment].

Authors:  Christoph Wendelmuth; Stefan Wirz; Misel Torontali; Anne Gastmeier; Knud Gastmeier
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

6.  [Severity of chronic back pain. Assessment with the Mainz Pain Staging System].

Authors:  D Michalski; A Hinz
Journal:  Schmerz       Date:  2006-06       Impact factor: 1.107

7.  [Pain processing in patients with borderline personality disorder, fibromyalgia, and post-traumatic stress disorder].

Authors:  A Jochims; P Ludäscher; M Bohus; R-D Treede; C Schmahl
Journal:  Schmerz       Date:  2006-04       Impact factor: 1.107

8.  [Austrian interdisciplinary recommendations on pediatric perioperative pain management: background, aims, methods and key messages].

Authors:  W Jaksch; B Messerer; H Baumgart; C Breschan; G Fasching; G Grögl; C Justin; B Keck; B Kraus-Stoisser; A Lischka; M Mayrhofer; M Platzer; D Schoberer; W Stromer; B Urlesberger; M Vittinghoff; S Zaheri; A Sandner-Kiesling
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

Review 9.  [Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

Authors:  K Güttler; R Sabatowski
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

10.  [Risk assessment in pain therapy].

Authors:  D Schoeffel; H R Casser; M Bach; H G Kress; R Likar; H Locher; W Steinleitner; M Strohmeier; H Brunner; R D Treede; W Zieglgänsberger; J Sandkühler
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.